Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Editas Medicine Inc (8EM) operate in?
Editas Medicine Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Editas Medicine Inc (8EM) current stock price?
As of the latest data, Editas Medicine Inc stock price is €2.10, with a previous close of €2.16. Editas Medicine Inc lost -€0.06 in the last trading session, representing a -2.78% loss.
What is Editas Medicine Inc (8EM) current market capitalization?
Editas Medicine Inc market cap is approximately 322.52 million.
What is Editas Medicine Inc (8EM) Earnings Per Share (EPS)?
The trailing EPS is -€0.58.
What is Editas Medicine Inc (8EM) EBITDA?
Editas Medicine Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.67 million.
Does Editas Medicine Inc (8EM) pay dividends?
No. Editas Medicine Inc does not pay a dividend.
When is Editas Medicine Inc (8EM) next earnings report?
Editas Medicine Inc is expected to release its next earnings report on September 30, 2026.
What is Editas Medicine Inc (8EM) beta (volatility) score?
Editas Medicine Inc has a beta of 2.000, suggesting it is more volatile than the market.
